Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial of M6620 (VX-970, Berzosertib) in Combination With the Topoisomerase I Inhibitor Irinotecan in Patients With Advanced Solid Tumors

NCT02595931 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02595931
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02595931 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial of M6620 (VX-970, Berzosertib) in Combination With the Topoisomerase I Inhibitor Irinotecan in Patients With Advanced Solid Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 22, 2016
Completion date
March 6, 2027
Enrollment
66 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal carcinoma, metastatic lung small cell carcinoma, metastatic malignant solid neoplasm, metastatic pancreatic carcinoma, refractory colorectal carcinoma, refractory lung small cell carcinoma, refractory malignant solid neoplasm, refractory pancreatic carcinoma, stage iii colorectal cancer ajcc v8, stage iii lung cancer ajcc v8, stage iii pancreatic cancer ajcc v8, stage iv colorectal cancer ajcc v8, stage iv lung cancer ajcc v8, stage iv pancreatic cancer ajcc v8, unresectable colorectal carcinoma, unresectable lung small cell carcinoma, unresectable malignant solid neoplasm, unresectable pancreatic carcinoma